Founded in 1995, Zhongyuan Concord Cell Genetic Engineering Co., Ltd. is a listed company, a well-known brand of biological resource storage projects, and a comprehensive enterprise integrating cell storage, genetic testing and clinical reagent research and development, anti-aging and beauty cosmetics production
Cell-Genomics Engineering Co., Ltd. (hereinafter referred to as "Cell-Gene" is one of the earliest companies in China to invest in biological resource storage projects, and is also the only life science and technology enterprise in China (stock code 600645 driven by the dual-core of "cells and genes"). The company has domestic advanced cell technology and a large cell resource storage network, with a cell storage capacity of more than 300,000 copies.
The company adheres to the core strategy of "cell gene" dual-nucleus development, and its main business includes: neonatal stem cell storage business; neonatal adult genetic testing, advanced gene sequencing equipment development, biochemical reagent R&D and production and clinical testing business; Adult cell storage business such as immune cell storage, adipocyte storage, and odontogenic stem cell storage; anti-aging and beauty cosmetics business featuring cell and gene technology; With the new model of "Internet Health", it integrates online and offline sales and service promotion of life bank cards and other businesses.
After 17 years of operation, Zhongyuan Concord has developed into a leading life science and technology industry group in China. The company has a number of well-known domestic subsidiaries such as Xiehe Stem Cell Genetic Engineering Co., Ltd., Shanghai Zhicheng Biotechnology Co., Ltd., Heze Biotechnology Co., Ltd., Tianjin Heze Stem Cell Technology Co., Ltd., Zhongyuan Xiehe Gene Technology Co., Ltd., and has established two overseas subsidiaries in the United States, such as Zhongyuan Xiehe (USA) Co., Ltd. and Zhongyuan Xiehe (USA) Biotechnology Transformation Center, which has vigorously opened the pace of global layout.
Through the strategic layout in cell storage, genetic testing, biotherapeutic technology, pharmaceutical, life big data, etc., we are building a cutting-edge, inclusive and innovative "precision medicine" platform, bringing the freshest technology, the most first-class talents, and the most potential companies and projects to this open and inclusive platform, so as to promote cutting-edge scientific and technological achievements to serve the public health as soon as possible.
Future prospects
As a listed company in the life science and technology industry, while focusing on its own development, Zhongyuan Concord has always actively assumed social responsibilities, taking it as its own responsibility to improve the quality of life of all mankind, constantly strengthening and expanding its national industrial brand, and ranking among the world's leading biotechnology ranks.
